The
Both moves culminate four years of presidential threats to companies in the drug supply chain to reduce prices or bow to regulations. It’s not clear how the incoming Biden administration will handle Trump’s legacy. Regardless the move could leave
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.